Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1046 - 1052
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121046
Publié en ligne 15 décembre 2009
  1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discovery 2006; 5 : 147–59. [Google Scholar]
  2. Wu AM, Senter PD. Arming antibodies : prospects and challenges for immunoconjugates. Nat Biotech 2005; 23 : 1137–46. [Google Scholar]
  3. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999; 17 : 478–84. [Google Scholar]
  4. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharm 2005; 5 : 543–9. [Google Scholar]
  5. Chari RVJ. Targeted cancer therapy : conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41 : 98–107. [Google Scholar]
  6. Amadori S, Stasi R. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukaemia. Curr Opin Hematol 2008; 15 : 95–100. [Google Scholar]
  7. Stasi R. Gemtuzumab ozogamicin : an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther 2008; 8 : 527–40. [Google Scholar]
  8. Walters RB, Gooley TA, Van Der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukaemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109 : 4168–70. [Google Scholar]
  9. Di Joseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103 : 1807–14. [Google Scholar]
  10. Chan SY, Gordon AN, Coleman RE, et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hctM01-calicheamicin) in patient with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003; 52 : 243–8. [Google Scholar]
  11. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjuguate. Cancer Res 2008; 68 : 9280–90. [Google Scholar]
  12. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.Cancer Res 2006; 66 : 4426–33 [Google Scholar]
  13. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005; 11 : 843–52. [Google Scholar]
  14. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12 : 1373–82. [Google Scholar]
  15. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates.Cancer Lett 2007; 255 : 232–40. [Google Scholar]
  16. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma : target and linker-drug selection. Cancer Res 2009; 69 : 2358–64. [Google Scholar]
  17. Law CH, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004; 10 : 7842–51. [Google Scholar]
  18. Ingle GS, Chan P, Elliott JM, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of antiCD19-drug conjugate. Br J Haematol 2007; 140 : 46–58. [Google Scholar]
  19. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006; 66 : 3214–21. [Google Scholar]
  20. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21 : 778–84. [Google Scholar]
  21. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery : effect of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17 : 114–24. [Google Scholar]
  22. Ojima I. Guided molecular missiles for tumor-targeting chemotherapy : case studies using the second generation taxoids as warheads. Acc Chem Res 2008; 41 : 108–19. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.